CTOR

0.17% 0.0012

시간 외 거래: .71 -0.000100 -0.01%

Citius Oncology Inc (CTOR)

개요 뉴스 가격 이력 토론 예측

Relative Volume:

Citius Oncology Inc Stock (CTOR) Company Profile

Citius Oncology Inc

Healthcare (1100)

(908) 967-6677

11 COMMERCE DRIVE, CRANFORD

최신 SEC 제출 서류

CTOR's Discussions on Twitter

Compare CTOR vs TAK, HLN, TEVA, ZTS, UTHR

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
CTOR Citius Oncology Inc	0.7101	65.91M	5.61M	-42.51M	-16.86M	-0.466
TAK Takeda Pharmaceutical Co Adr	16.96	53.37B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.84	42.80B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	34.65	41.09B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	76.29	31.62B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	563.70	23.23B	3.17B	1.29B	1.01B	27.09

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2025-09-23	업그레이드	Maxim Group	Hold → Buy
2024-11-27	개시	Maxim Group	Buy

Citius Oncology Inc 주식(CTOR)의 최신 뉴스

Citius Oncology Inc (CTOR) 재무 분석

Citius Oncology Inc (CTOR)

Citius Oncology Inc Stock (CTOR) Company Profile

Compare CTOR vs TAK, HLN, TEVA, ZTS, UTHR

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

Citius Oncology Inc 주식(CTOR)의 최신 뉴스

CTOR Q1 2026 Earnings: Significant EPS Miss Signals Ongoing Development-Stage ChallengesEarnings Yield Analysis - dars.gov.et

Enterprise value to EBITDA forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView

Price to sales forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView

Citius Oncology, Inc. Actuals & Estimates (NASDAQ:CTOR) - TradingView

Citius Oncology, Inc. Actuals & Estimates (BOATS:CTOR) - TradingView

Price to earnings forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView

Citius Oncology Inc (CTOR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Price to book forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView

CTOR Forecast — Price Target — Prediction for 2027 - TradingView

Enterprise value to revenue forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView

CTOR Q1 2026 Earnings: Wider-Than-Expected Loss Alarms InvestorsEarnings Per Share - dars.gov.et

Citius Oncology Inc (CTOR) Valuation: PE, PB & Fair Value Analysis - TradingKey

Citius Oncology Inc (CTOR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

CITIUS ONCOLOGY INC (CTOR) Stock Chart - ChartMill

Citius Oncology Inc (CTOR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Citius Oncology Inc (CTOR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Citius Oncology Inc (CTOR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Citius Oncology Inc (CTOR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Citius Oncology Inc (CTOR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Citius Oncology Inc (CTOR) Institutional Confidence - TradingKey

CTOR Q1 2026 Earnings: Deep EPS Miss Highlights Pre‑Revenue ChallengesEstimate Revision Count - newsline.com

Citius Oncology Inc. (CTOR) Gains 6% as Buyers Defend Key SupportSentiment Divergence - newsline.com

CTOR Q1 2026 Earnings: Significant EPS Miss Highlights Continued Investment in PipelineRevenue Surprise History - newsline.com

Citius Oncology (CTOR) Edges Higher as Stock Hovers Near SupportMcClellan Summation - newsline.com

CTXR News | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill

[EFFECT] CITIUS ONCOLOGY, INC. SEC Filing - Stock Titan

Citius Oncology (CTOR) stake updated by majority holder Citius Pharma - Stock Titan

Citius Oncology, Inc. Financial Disclosures & SEC Filings - TradingView

[EFFECT] Citius Pharmaceuticals, Inc. SEC Filing - Stock Titan

Citius Oncology Reports Promising Phase 1 Results for LYMPHIR Plus Pembrolizumab in Recurrent Gynecologic Cancers at ASCO 2026 123 - Minichart

Citius Oncology Highlights Promising Phase 1 Results for LYMPHIR® Plus Pembrolizumab in Recurrent Gynecologic Cancers at ASCO 2026 123 - Minichart

Citius Highlights LYMPHIR Combo Data in Gynecologic Cancers - TipRanks

Citius Oncology (CTOR) registers 6.8M warrant shares; highlights Phase 1 LYMPHIR data - Stock Titan

Citius Oncology (NASDAQ: CTOR) highlights Phase 1 LYMPHIR plus pembrolizumab results - Stock Titan

Citius Oncology Highlights Phase 1 Data in an Investigator-Initi - GuruFocus

Citius Oncology (CTXR) Presents Promising Data on LYMPHIR for Gy - GuruFocus

Citius Oncology presents study data on LYMPHIR combination By Investing.com - Investing.com Australia

Citius Oncology presents study data on LYMPHIR combination - Investing.com

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies - PR Newswire

Citius Oncology (NASDAQ: CTOR) clears potential $25M loan conversions and large warrants - Stock Titan

Citius Oncology (Nasdaq: CTOR) registers 32.9M shares tied to warrants and loan conversion - Stock Titan

CTOR Q1 2026 Earnings: Significant EPS Miss Amid Pre-Revenue PhaseBook Value Growth - thelegaladvocate.com

Number of shareholders of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView

Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combi - GuruFocus

Citius Oncology study combining LYMPHIR with pembrolizumab selected for ASCO presentation - Investing.com Nigeria

Citius Oncology study combining LYMPHIR with pembrolizumab selected for ASCO presentation By Investing.com - Investing.com South Africa

CTXRCitius Pharmaceuticals Inc Stock Price and Quote - Finviz

CTORCitius Oncology Inc Stock Price and Quote - Finviz

Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting - PR Newswire

Citius Oncology Q1 2026 Earnings: Wide EPS Miss Highlights Pre-Revenue ChallengesManagement Guidance Update - newsline.com

Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts? - Yahoo Finance

Citius Oncology Inc (CTOR) 재무 분석

매출

순이익

현금흐름

주당 순 이익

CTOR과 유사한 종목